Phar 7.06(1)(1) The repackaging for stock process is conducted under conditions that ensure the integrity of the drug. Phar 7.06(2)(2) Products repackaged for stock shall include a beyond use date that ensures the integrity of the drug. Phar 7.06(3)(3) The repackaged container shall be selected to mitigate adulteration from light, temperature and humidity. Phar 7.06(4)(4) The repackaged for stock drugs are labeled physically or electronically with all the following components: Phar 7.06(4)(b)3.3. Name of manufacturer or distributer of the drug product, and the manufacturer lot number. Phar 7.06(5)(5) Records of all repackaging for stock operations are maintained and include all the following: Phar 7.06(5)(a)(a) Name, strength, form, quantity per container, and quantity of containers. Phar 7.06(5)(b)(b) NDC number or the name of the manufacturer or distributor of the drug product. Phar 7.06(5)(d)(d) Original container’s expiration date and the beyond-use date for the new containers. Phar 7.06(5)(e)(e) First and last name of the pharmacist or delegate that repackaged the drug and the first and last name of the pharmacist that verified the accuracy of the repackaging. Phar 7.06 HistoryHistory: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21. Phar 7.07(1)(1) A final check of accuracy and correctness is required for any prescription drug product or device dispensed and shall include all of the following: Phar 7.07(1)(a)(a) Verifying label is correct and meets labeling requirements. Phar 7.07(2)(2) For all prescription drug products or devices dispensed by a pharmacist, the prescription record shall identify the pharmacist responsible for each part of the final check. If sub. (1) (a) or (b) is completed by a pharmacy product verification technician under s. Phar 7.14 or automated technology under s. Phar 7.55, the prescription record shall identify the pharmacy product verification technician performing the check. Phar 7.07 HistoryHistory: CR 19-145: cr. Register December 2020 No. 780, eff. 1-1-21; EmR2303: emerg. am. (2), eff. 2-3-23; CR 23-072: am. (2) Register August 2024 No. 824, eff 9-1-24. Phar 7.08(1)(1) A pharmacist shall provide the patient or patient’s agent consultation to optimize proper use of a prescription drug or device, that meets any of the following: